Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice

Prescribing the right medication, at the right dose, to the right patient is the goal of every physician. Pharmacogenomic information is an emerging tool that can be used to deliver precision medicine. In this review, we discuss the pharmacogenomics of available PPIs, racial differences of CYP2C19 a...

Full description

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 2021-12, Vol.66 (12), p.4120-4127
Main Authors: Harris, Dana M., Stancampiano, Fernando F., Burton, M. Caroline, Moyer, Ann M., Schuh, Michael J., Valery, Jose R., Bi, Yan
Format: Article
Language:English
Subjects:
Acids
Biochemistry
Clinical medicine
Clopidogrel
Cytochrome
Cytochrome P-450
Disease
Drug dosages
Drug stores
FDA approval
Gastroenterology
Gastroesophageal reflux
Gastrointestinal diseases
Genomics
Genotype & phenotype
Hepatology
Internal medicine
Medicine
Medicine & Public Health
Metabolism
Oncology
Pantoprazole
Pediatrics
Pharmacogenetics
Polymorphism
Race
Racial differences
Review
Small intestine
Transplant Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prescribing the right medication, at the right dose, to the right patient is the goal of every physician. Pharmacogenomic information is an emerging tool that can be used to deliver precision medicine. In this review, we discuss the pharmacogenomics of available PPIs, racial differences of CYP2C19 and how PPI pharmacogenomics affects the treatment of common gastrointestinal diseases. We also provide practical guidance on when to order pharmacogenomic testing, which test to order, and how to modify treatment based on published guidelines.
ISSN:0163-2116
1573-2568
DOI:10.1007/s10620-020-06814-1